-
1
-
-
84892590856
-
Antibodies to watch in 2014
-
Reichert J.M. Antibodies to watch in 2014. mAbs 2014, 6:5-14.
-
(2014)
mAbs
, vol.6
, pp. 5-14
-
-
Reichert, J.M.1
-
2
-
-
52449112071
-
Heterogeneity of monoclonal antibodies
-
Liu H., Gaza-Bulseco G., Faldu D., Chumsae C., Sun J. Heterogeneity of monoclonal antibodies. J. Pharm. Sci. 2008, 97:2426-2447.
-
(2008)
J. Pharm. Sci.
, vol.97
, pp. 2426-2447
-
-
Liu, H.1
Gaza-Bulseco, G.2
Faldu, D.3
Chumsae, C.4
Sun, J.5
-
3
-
-
84872503060
-
Characterization of therapeutic antibodies and related products
-
Beck A., Wagner-Rousset E., Ayoub D., Van Dorsselaer A., Sanglier-Cianférani S. Characterization of therapeutic antibodies and related products. Anal. Chem. 2012, 85:715-736.
-
(2012)
Anal. Chem.
, vol.85
, pp. 715-736
-
-
Beck, A.1
Wagner-Rousset, E.2
Ayoub, D.3
Van Dorsselaer, A.4
Sanglier-Cianférani, S.5
-
4
-
-
78650543555
-
Impact of product-related factors on immunogenocity of biotherapeutics
-
Singh S.K. Impact of product-related factors on immunogenocity of biotherapeutics. J. Pharm. Sci. 2011, 100:354-387.
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 354-387
-
-
Singh, S.K.1
-
5
-
-
84862212634
-
Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach
-
Eon-Duval A., Broly H., Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol. Prog. 2012, 28:608-622.
-
(2012)
Biotechnol. Prog.
, vol.28
, pp. 608-622
-
-
Eon-Duval, A.1
Broly, H.2
Gleixner, R.3
-
6
-
-
84870952537
-
Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates
-
Hong P., Koza S., Bouvier E.S.P. Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J. Liq. Chromatogr. Relat. Technol. 2012, 35:2923-2950.
-
(2012)
J. Liq. Chromatogr. Relat. Technol.
, vol.35
, pp. 2923-2950
-
-
Hong, P.1
Koza, S.2
Bouvier, E.S.P.3
-
7
-
-
84908606572
-
Theory and practice of size exclusion chromatography for the analysis of protein aggregates
-
Fekete S., Beck A., Veuthey J.-L., Guillarme D. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J. Pharm. Biomed. Anal. 2014, 101:161-173.
-
(2014)
J. Pharm. Biomed. Anal.
, vol.101
, pp. 161-173
-
-
Fekete, S.1
Beck, A.2
Veuthey, J.-L.3
Guillarme, D.4
-
8
-
-
8344224534
-
Characterizing Biological Products and Assessing Comparability following manufacturing changes
-
Chirino A.J., Mire-Sluis A. Characterizing Biological Products and Assessing Comparability following manufacturing changes. Nat. Biotechnol. 2004, 22:1383-1391.
-
(2004)
Nat. Biotechnol.
, vol.22
, pp. 1383-1391
-
-
Chirino, A.J.1
Mire-Sluis, A.2
-
9
-
-
77951267552
-
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products
-
Carpenter J.F., Randolph T.W., Jiskoot W., Crommelin D.J.A., Middaugh C.R., Winter G. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J. Pharm. Sci. 2010, 99:2200-2208.
-
(2010)
J. Pharm. Sci.
, vol.99
, pp. 2200-2208
-
-
Carpenter, J.F.1
Randolph, T.W.2
Jiskoot, W.3
Crommelin, D.J.A.4
Middaugh, C.R.5
Winter, G.6
-
10
-
-
77949807386
-
The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals
-
Arakawa T., Ejima D., Li T., Philo J.S. The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals. J. Pharm. Sci. 2010, 99:1674-1692.
-
(2010)
J. Pharm. Sci.
, vol.99
, pp. 1674-1692
-
-
Arakawa, T.1
Ejima, D.2
Li, T.3
Philo, J.S.4
-
11
-
-
84860259177
-
Quantitative impurity analysis of monoclonal antibody size heterogeneity by CE-LIF: example of development and validation through a quality-by-design framework
-
Michels D.A., Parker M., Salas-Solano O. Quantitative impurity analysis of monoclonal antibody size heterogeneity by CE-LIF: example of development and validation through a quality-by-design framework. Electrophoresis 2012, 33:815-826.
-
(2012)
Electrophoresis
, vol.33
, pp. 815-826
-
-
Michels, D.A.1
Parker, M.2
Salas-Solano, O.3
-
12
-
-
84867199315
-
On-line coupling of size exclusion chromatography with mixed-mode liquid chromatography for comprehensive profiling of biopharmaceutical drug product
-
He Y., Friese O.V., Schlittler M.R., Wang Q., Yang X., Bass L.A., Jones M.T. On-line coupling of size exclusion chromatography with mixed-mode liquid chromatography for comprehensive profiling of biopharmaceutical drug product. J. Chromatogr. A 2012, 1262:122-129.
-
(2012)
J. Chromatogr. A
, vol.1262
, pp. 122-129
-
-
He, Y.1
Friese, O.V.2
Schlittler, M.R.3
Wang, Q.4
Yang, X.5
Bass, L.A.6
Jones, M.T.7
-
13
-
-
34250662668
-
Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography
-
Yang J., Wang S., Liu J., Raghani A. Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography. J. Chromatogr. A 2007, 1156:174-182.
-
(2007)
J. Chromatogr. A
, vol.1156
, pp. 174-182
-
-
Yang, J.1
Wang, S.2
Liu, J.3
Raghani, A.4
-
14
-
-
84872267390
-
Facile method of quantification for oxidized tryptophan degradants of monoclonal antibody by mixed mode ultra performance liquid chromatography
-
Wong C., Strachan-Mills C., Burman S. Facile method of quantification for oxidized tryptophan degradants of monoclonal antibody by mixed mode ultra performance liquid chromatography. J. Chromatogr. A 2012, 1270:153-161.
-
(2012)
J. Chromatogr. A
, vol.1270
, pp. 153-161
-
-
Wong, C.1
Strachan-Mills, C.2
Burman, S.3
-
15
-
-
84875275370
-
Critical evaluation of fast size exclusion chromatographic separations of protein aggregates, applying sub-2μm particles
-
Fekete S., Ganzler K., Guillarme D. Critical evaluation of fast size exclusion chromatographic separations of protein aggregates, applying sub-2μm particles. J. Pharm. Biomed. Anal. 2013, 78-79:141-149.
-
(2013)
J. Pharm. Biomed. Anal.
, pp. 141-149
-
-
Fekete, S.1
Ganzler, K.2
Guillarme, D.3
-
16
-
-
81855164598
-
A sub-two minutes method for monoclonal antibody-aggregate quantification using parallel interlaced size exclusion high performance liquid chromatography
-
Diederich P., Hansen S.K., Oelmeier S.A., Stolzenberger B., Hubbuch J. A sub-two minutes method for monoclonal antibody-aggregate quantification using parallel interlaced size exclusion high performance liquid chromatography. J. Chromatogr. A 2011, 1218:9010-9018.
-
(2011)
J. Chromatogr. A
, vol.1218
, pp. 9010-9018
-
-
Diederich, P.1
Hansen, S.K.2
Oelmeier, S.A.3
Stolzenberger, B.4
Hubbuch, J.5
-
17
-
-
79953237219
-
Ultra-High-Pressure LC. (UHPLC) for therapeutic protein characterization
-
Jeong J., Zhang T., Zhang J., Kao Y.H. Ultra-High-Pressure LC. (UHPLC) for therapeutic protein characterization. Am. Pharm. Rev. 2011, 14:44.
-
(2011)
Am. Pharm. Rev.
, vol.14
, pp. 44
-
-
Jeong, J.1
Zhang, T.2
Zhang, J.3
Kao, Y.H.4
-
18
-
-
84924249335
-
A high throughput ultra performance size exclusion chromatography assay for the analysis of aggregates and fragments of monoclonal antibodies
-
Mou X., Yang X., Li H., Ambrogelly A., Pollard D.J. A high throughput ultra performance size exclusion chromatography assay for the analysis of aggregates and fragments of monoclonal antibodies. Pharm. Bioprocess. 2014, 2:141-156.
-
(2014)
Pharm. Bioprocess.
, vol.2
, pp. 141-156
-
-
Mou, X.1
Yang, X.2
Li, H.3
Ambrogelly, A.4
Pollard, D.J.5
-
19
-
-
80054970831
-
On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format
-
Alvarez M., Tremintin G., Wang J., Eng M., Kao Y.-H., Jeong J., Ling V.T., Borisov O.V. On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format. Anal. Biochem. 2011, 419:17-25.
-
(2011)
Anal. Biochem.
, vol.419
, pp. 17-25
-
-
Alvarez, M.1
Tremintin, G.2
Wang, J.3
Eng, M.4
Kao, Y.-H.5
Jeong, J.6
Ling, V.T.7
Borisov, O.V.8
-
20
-
-
70450201380
-
Interlaced size exclusion liquid chromatography of monoclonal antibodies
-
Farnan D., Moreno G.T., Stults J., Becker A., Tremintin G., van Gils M. Interlaced size exclusion liquid chromatography of monoclonal antibodies. J. Chromatogr. A 2009, 1216:8904-8909.
-
(2009)
J. Chromatogr. A
, vol.1216
, pp. 8904-8909
-
-
Farnan, D.1
Moreno, G.T.2
Stults, J.3
Becker, A.4
Tremintin, G.5
van Gils, M.6
-
21
-
-
84924233658
-
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability
-
Sharma V.K., Patapoff T.W., Kabakoff B., Pai S., Hilario E., Zhang B., Li C., Borisov O., Kelley R.F., Chorny I., Zhou J.Z., Dill K.A., Swartz T.E. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc. Nat. Acad. Sci. 2014, 111:18601-18606.
-
(2014)
Proc. Nat. Acad. Sci.
, vol.111
, pp. 18601-18606
-
-
Sharma, V.K.1
Patapoff, T.W.2
Kabakoff, B.3
Pai, S.4
Hilario, E.5
Zhang, B.6
Li, C.7
Borisov, O.8
Kelley, R.F.9
Chorny, I.10
Zhou, J.Z.11
Dill, K.A.12
Swartz, T.E.13
-
22
-
-
14744289246
-
Non-enzymatic hinge region fragmentation of antibodies in solution
-
Cordoba A.J., Shyong B.-J., Breen D., Harris R.J. Non-enzymatic hinge region fragmentation of antibodies in solution. J. Chromatogr. B 2005, 818:115-121.
-
(2005)
J. Chromatogr. B
, vol.818
, pp. 115-121
-
-
Cordoba, A.J.1
Shyong, B.-J.2
Breen, D.3
Harris, R.J.4
-
23
-
-
67349280131
-
Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine
-
Ouellette D., Alessandri L., Piparia R., Aikhoje A., Chin A., Radziejewski C., Correia I. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal. Biochem. 2009, 389:107-117.
-
(2009)
Anal. Biochem.
, vol.389
, pp. 107-117
-
-
Ouellette, D.1
Alessandri, L.2
Piparia, R.3
Aikhoje, A.4
Chin, A.5
Radziejewski, C.6
Correia, I.7
-
24
-
-
34250182367
-
Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage
-
Cohen S.L., Price C., Vlasak J. Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J. Am. Chem. Soc. 2007, 129:6976-6977.
-
(2007)
J. Am. Chem. Soc.
, vol.129
, pp. 6976-6977
-
-
Cohen, S.L.1
Price, C.2
Vlasak, J.3
|